These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21540237)

  • 21. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor.
    Ikuta K; Ota T; Zhuo L; Urakawa H; Kozawa E; Hamada S; Kimata K; Ishiguro N; Nishida Y
    Int J Cancer; 2017 Jan; 140(2):469-479. PubMed ID: 27706810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop.
    Syed ZA; Yin W; Hughes K; Gill JN; Shi R; Clifford JL
    BMC Cancer; 2011 May; 11():180. PubMed ID: 21595927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
    Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
    Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
    [No Abstract]   [Full Text] [Related]  

  • 26. Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors.
    Daudigeos-Dubus E; Le Dret L; Bawa O; Opolon P; Vievard A; Villa I; Bosq J; Vassal G; Geoerger B
    Int J Oncol; 2017 Jan; 50(1):203-211. PubMed ID: 27922668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.
    Navis AC; Bourgonje A; Wesseling P; Wright A; Hendriks W; Verrijp K; van der Laak JA; Heerschap A; Leenders WP
    PLoS One; 2013; 8(3):e58262. PubMed ID: 23484006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
    Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
    Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
    Jahangiri A; De Lay M; Miller LM; Carbonell WS; Hu YL; Lu K; Tom MW; Paquette J; Tokuyasu TA; Tsao S; Marshall R; Perry A; Bjorgan KM; Chaumeil MM; Ronen SM; Bergers G; Aghi MK
    Clin Cancer Res; 2013 Apr; 19(7):1773-83. PubMed ID: 23307858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic Status of
    Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
    Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
    Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
    Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
    Smith BD; Kaufman MD; Leary CB; Turner BA; Wise SC; Ahn YM; Booth RJ; Caldwell TM; Ensinger CL; Hood MM; Lu WP; Patt TW; Patt WC; Rutkoski TJ; Samarakoon T; Telikepalli H; Vogeti L; Vogeti S; Yates KM; Chun L; Stewart LJ; Clare M; Flynn DL
    Mol Cancer Ther; 2015 Sep; 14(9):2023-34. PubMed ID: 26285778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.
    Surriga O; Rajasekhar VK; Ambrosini G; Dogan Y; Huang R; Schwartz GK
    Mol Cancer Ther; 2013 Dec; 12(12):2817-26. PubMed ID: 24140933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
    Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
    Chen HM; Tsai CH; Hung WC
    Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
    Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
    BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.
    Kentsis A; Reed C; Rice KL; Sanda T; Rodig SJ; Tholouli E; Christie A; Valk PJ; Delwel R; Ngo V; Kutok JL; Dahlberg SE; Moreau LA; Byers RJ; Christensen JG; Vande Woude G; Licht JD; Kung AL; Staudt LM; Look AT
    Nat Med; 2012 Jul; 18(7):1118-22. PubMed ID: 22683780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
    Mohan P; Castellsague J; Jiang J; Allen K; Chen H; Nemirovsky O; Spyra M; Hu K; Kluwe L; Pujana MA; Villanueva A; Mautner VF; Keats JJ; Dunn SE; Lazaro C; Maxwell CA
    Oncotarget; 2013 Jan; 4(1):80-93. PubMed ID: 23328114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
    Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
    Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.